The National Institute for Health and Care Excellence (NICE) has recommended that a weekly injection to aid weight loss in overweight and obese adults should be funded on the NHS. In draft guidance, published on 8 February 2022 (https://www.nice.org.uk/guidance/indevelopment/gid-ta10765/consultation/html-content-2) , NICE recommends semaglutide (Wegovy; Novo Nordisk)-which is already indicated for the treatment of type 2 diabetes mellitus (https://bnf.nice.org.uk/drug/semaglutide.html)-should be considered in adults with at least one weight-related condition and a body mass index (BMI) of at least 35.
展开▼
